"1041 DEVELOPMENT OF A NOMOGRAM TO PREDICT INDIVIDUAL BENEFIT ATTAINED FROM ADDITION OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF STAGE II COLON CANCER" by Clay M. Merritt

Article

1041 DEVELOPMENT OF A NOMOGRAM TO PREDICT INDIVIDUAL BENEFIT ATTAINED FROM ADDITION OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF STAGE II COLON CANCER

Gastroenterology (2020)

Clay M. Merritt
Shu-Ching Chang
Gary L. Grunkemeier
Scott Steele
Melanie Goldfarb
Daniel Nelson

Link

Disciplines

Oncology,
Internal Medicine and
Medicine and Health Sciences

Publication Date

May 1, 2020

DOI

10.1016/S0016-5085(20)34542-X

Citation Information

Clay M. Merritt, Shu-Ching Chang, Gary L. Grunkemeier, Scott Steele, et al.. "1041 DEVELOPMENT OF A NOMOGRAM TO PREDICT INDIVIDUAL BENEFIT ATTAINED FROM ADDITION OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF STAGE II COLON CANCER" Gastroenterology Vol. 158 Iss. 6 (2020)
Available at: http://works.bepress.com/gary-grunkemeier/2/